
Adam S Cheifetz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5272211/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Incidence and Management of Infusion Reactions To Infliximab: A Large Center Experience. American Journal of Gastroenterology, 2003, 98, 1315-1324.	0.4	442
2	The Risk of Retention of the Capsule Endoscope in Patients with Known or Suspected Crohn's Disease. American Journal of Gastroenterology, 2006, 101, 2218-2222.	0.4	358
3	Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis. American Journal of Gastroenterology, 2013, 108, 40-47.	0.4	298
4	Crohn Disease: Epidemiology, Diagnosis, and Management. Mayo Clinic Proceedings, 2017, 92, 1088-1103.	3.0	292
5	Functional variants in the <i>LRRK2</i> gene confer shared effects on risk for Crohn's disease and Parkinson's disease. Science Translational Medicine, 2018, 10, .	12.4	273
6	Ulcerative Colitis. Mayo Clinic Proceedings, 2014, 89, 1553-1563.	3.0	236
7	Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 1655-1668.e3.	4.4	214
8	Systematic Review and Meta-analysis on the Effects of Thiopurines on Birth Outcomes from Female and Male Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 15-22.	1.9	211
9	Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 1996-2003.	1.9	198
10	Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clinical Gastroenterology and Hepatology, 2017, 15, 1580-1588.e3.	4.4	181
11	Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2019, 17, 139-147.	4.4	138
12	Management of Active Crohn Disease. JAMA - Journal of the American Medical Association, 2013, 309, 2150.	7.4	118
13	Complementary and Alternative Medicines Used by Patients WithÂInflammatory Bowel Diseases. Gastroenterology, 2017, 152, 415-429.e15.	1.3	114
14	Capsule Endoscopy Retention: Is it a Complication?. Journal of Clinical Gastroenterology, 2006, 40, 688-691.	2.2	110
15	Histologic Markers of Inflammation in Patients With Ulcerative Colitis in Clinical Remission. Clinical Gastroenterology and Hepatology, 2013, 11, 991-996.	4.4	109
16	Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. Clinical Gastroenterology and Hepatology, 2015, 13, 2233-2240.e2.	4.4	109
17	The Burden of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 545-552.	1.9	106
18	Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2019, 13, 976-981.	1.3	104

#	Article	IF	CITATIONS
19	The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2013, 37, 786-794.	3.7	96
20	Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mount Sinai Journal of Medicine, 2005, 72, 250-6.	1.9	94
21	A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2021, 116, 2014-2025.	0.4	93
22	Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 804-810.	1.3	91
23	Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterology, 2016, 7, 289-300.	1.8	88
24	Varicella zoster virus infection in inflammatory bowel disease. Inflammatory Bowel Diseases, 2012, 18, 2392-2403.	1.9	87
25	Infliximab in inflammatory bowel disease. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231983844.	2.5	82
26	Meta-analysis of dye-based chromoendoscopy compared withÂstandard- and high-definition white-light endoscopy in patients with inflammatory bowel disease at increased risk ofÂcolon cancer. Gastrointestinal Endoscopy, 2019, 90, 186-195.e1.	1.0	80
27	CD39 and CD161 Modulate Th17 Responses in Crohn's Disease. Journal of Immunology, 2014, 193, 3366-3377.	0.8	79
28	Predictors of Endoscopic Inflammation in Patients With Ulcerative Colitis in Clinical Remission. Inflammatory Bowel Diseases, 2013, 19, 779-784.	1.9	71
29	Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert Review of Clinical Immunology, 2019, 15, 837-848.	3.0	71
30	Cyclosporine is Safe and Effective in Patients With Severe Ulcerative Colitis. Journal of Clinical Gastroenterology, 2011, 45, 107-112.	2.2	66
31	Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease. Inflammatory Bowel Diseases, 2018, 24, 2266-2271.	1.9	65
32	Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies. Clinical Immunology, 2019, 206, 9-14.	3.2	63
33	Therapeutic Drug Monitoring During Induction of Anti–Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 1510-1515.	1.9	62
34	Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2Â. Gut, 2007, 56, 1210-1217.	12.1	60
35	Melanin-concentrating hormone as a mediator of intestinal inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10613-10618.	7.1	59
36	Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. The Lancet Gastroenterology and Hepatology, 2022, 7, 171-185.	8.1	57

#	Article	IF	CITATIONS
37	Vitamin D Levels in Adults with Crohn's Disease Are Responsive to Disease Activity and Treatment. Inflammatory Bowel Diseases, 2014, 20, 856-860.	1.9	56
38	Biologic Concentration Testing in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 1.	1.9	56
39	Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2018, 63, 3067-3073.	2.3	54
40	Characterization of Human CD39+ Th17 Cells with Suppressor Activity and Modulation in Inflammatory Bowel Disease. PLoS ONE, 2014, 9, e87956.	2.5	54
41	Capsule endoscopy for small-bowel evaluation in Crohn's disease. Gastrointestinal Endoscopy, 2011, 74, 167-175.	1.0	51
42	In Vitro Fertilization Is Successful in Women With Ulcerative Colitis and Ileal Pouch Anal Anastomosis. American Journal of Gastroenterology, 2015, 110, 792-797.	0.4	51
43	A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF. Gastroenterology, 2016, 151, 710-723.e2.	1.3	51
44	<scp>CD</scp> 73 is a phenotypic marker of effector memory <scp>T</scp> h17 cells in inflammatory bowel disease. European Journal of Immunology, 2012, 42, 3062-3072.	2.9	50
45	Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF Therapy. American Journal of Gastroenterology, 2017, 112, 673-676.	0.4	50
46	The Diagnosis and Treatment of Pouchitis in Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2004, 38, S44-S50.	2.2	49
47	Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflammatory Bowel Diseases, 2012, 18, 1057-1063.	1.9	48
48	Meta-analysis of Virtual-based Chromoendoscopy Compared With Dye-spraying Chromoendoscopy Standard and High-definition White Light Endoscopy in Patients With Inflammatory Bowel Disease at Increased Risk of Colon Cancer. Inflammatory Bowel Diseases, 2020, 26, 1319-1329.	1.9	48
49	The Appropriateness of Concomitant Immunomodulators With Anti–Tumor Necrosis Factor Agents for Crohn's Disease: One Size Does Not Fit All. Clinical Gastroenterology and Hepatology, 2010, 8, 655-659.	4.4	46
50	Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 2806-2814.	1.9	46
51	Factors that Affect Adherence to Surveillance Colonoscopy in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 534-539.	1.9	45
52	Abdominal phlegmons in Crohn's disease: Outcomes following antitumor necrosis factor therapy. Inflammatory Bowel Diseases, 2012, 18, 691-696.	1.9	42
53	Therapeutic drug monitoring in inflammatory bowel disease. Current Opinion in Gastroenterology, 2019, 35, 302-310.	2.3	42
54	Review article: emerging drug therapies in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 789-804.	3.7	38

#	Article	IF	CITATIONS
55	Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. Inflammatory Bowel Diseases, 2012, 18, 1608-1616.	1.9	36
56	Systematic Analysis Underlying the Quality of the Scientific Evidence and Conflicts of Interest in Interventional Medicine Subspecialty Guidelines. Mayo Clinic Proceedings, 2014, 89, 16-24.	3.0	36
57	Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation ofÂResults. Clinical Gastroenterology and Hepatology, 2016, 14, 1302-1309.	4.4	36
58	The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information. Inflammatory Bowel Diseases, 2019, 25, 427-435.	1.9	36
59	Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy). Gastroenterology Clinics of North America, 2014, 43, 543-563.	2.2	35
60	Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. Inflammatory Bowel Diseases, 2020, 26, 103-111.	1.9	34
61	Poor Documentation of Inflammatory Bowel Disease Quality Measures in Academic, Community, and Private Practice. Clinical Gastroenterology and Hepatology, 2016, 14, 421-428.e2.	4.4	33
62	Indications for Mode of Delivery in Pregnant Women with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 721-726.	1.9	33
63	A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 191-197.	1.9	33
64	Failure to Induce Oral Tolerance in Crohn's and Ulcerative Colitis Patients: Possible Genetic Risk. Annals of the New York Academy of Sciences, 2004, 1029, 225-238.	3.8	31
65	Evidence for a genetic defect in oral tolerance induction in inflammatory bowel disease. Inflammatory Bowel Diseases, 2006, 12, 82-88.	1.9	31
66	Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis. American Journal of Gastroenterology, 2021, 116, 1007-1014.	0.4	31
67	Infliximab: Use in inflammatory bowel disease. Current Treatment Options in Gastroenterology, 2005, 8, 187-196.	0.8	30
68	Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis — A prospective study. Journal of Crohn's and Colitis, 2010, 4, 171-175.	1.3	30
69	Herpes Zoster Vaccine Response in Inflammatory Bowel Disease Patients on Low-dose Immunosuppression. Inflammatory Bowel Diseases, 2016, 22, 1391-1396.	1.9	29
70	The Role of Mucosal Healing in the Treatment of Patients With Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology, 2014, 12, 103-117.	0.8	28
71	InÂVitro Fertilization in Women With Inflammatory Bowel Disease Is as Successful as in Women From the General Infertility Population. Clinical Gastroenterology and Hepatology, 2015, 13, 1641-1646.e3.	4.4	28
72	Management of acute severe ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2009, 3, 395-405.	3.0	25

#	Article	IF	CITATIONS
73	Meta-Analysis of the Placebo Response in Ulcerative Colitis. Digestive Diseases and Sciences, 2008, 53, 875-891.	2.3	23
74	Systematic Analysis Underlying the Quality of the Scientific Evidence and Conflicts of Interest in Gastroenterology Practice Guidelines. American Journal of Gastroenterology, 2013, 108, 1686-1693.	0.4	23
75	Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis. Annals of Gastroenterology, 2016, 29, 341-7.	0.6	23
76	Efficacy and Safety of Natalizumab in Crohn's Disease Patients Treated at 6 Boston Academic Hospitals. Inflammatory Bowel Diseases, 2013, 19, 2457-2463.	1.9	22
77	Attitudes to Mesalamine Questionnaire: A Novel Tool to Predict Mesalamine Nonadherence in Patients with IBD. American Journal of Gastroenterology, 2014, 109, 1850-1855.	0.4	21
78	Surgery for Ulcerative Colitis Is Associated with a High Rate of Readmissions at 30 Days. Inflammatory Bowel Diseases, 2015, 21, 2130-2136.	1.9	21
79	Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 1418-1424.	1.9	21
80	Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2018, 63, 761-767.	2.3	21
81	Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?. Gastroenterology, 2018, 154, 1201-1202.	1.3	20
82	Documented Compliance with Inflammatory Bowel Disease Quality Measures Is Poor. Digestive Diseases and Sciences, 2015, 60, 339-344.	2.3	19
83	Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. Current Opinion in Rheumatology, 2020, 32, 371-379.	4.3	19
84	Impact of Concomitant Immunomodulator Use on Long-Term Outcomes in Patients Receiving Scheduled Maintenance Infliximab. Digestive Diseases and Sciences, 2010, 55, 1413-1420.	2.3	18
85	Mycobacterium marinum : An Increasingly Common Opportunistic Infection in Patients on Infliximab. American Journal of Gastroenterology, 2012, 107, 1268-1269.	0.4	18
86	Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 2873-2878.	1.9	18
87	Systematic analysis of the quality of the scientific evidence and conflicts of interest in osteoarthritis of the hip and knee practice guidelines. Seminars in Arthritis and Rheumatism, 2016, 45, 379-385.	3.4	18
88	Prevalence and Lifetime Risk of Endoscopy-related Complications Among Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2013, 11, 1288-1293.	4.4	17
89	Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn's Disease. Journal of Crohn's and Colitis, 2017, 11, 1113-1123.	1.3	17
90	Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease. Journal of Clinical Medicine, 2020, 9, 3142.	2.4	17

#	Article	IF	CITATIONS
91	Patients With Low Drug Levels or Antibodies to a Prior Anti–Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti–Tumor Necrosis Factor. Clinical Gastroenterology and Hepatology, 2022, 20, 465-467.e2.	4.4	17
92	Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). BMJ Open, 2022, 12, e057656.	1.9	17
93	Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAgâ^') on anti-TNF therapy have a low rate of reactivation. Clinical Immunology, 2018, 191, 59-62.	3.2	16
94	Endogenous antisense RNA curbs CD39 expression in Crohn's disease. Nature Communications, 2020, 11, 5894.	12.8	16
95	Utility of CT in the Emergency Department in Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 793-800.	1.9	15
96	Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2021, 19, 839-841.e2.	4.4	15
97	Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2019, 15, 656-665.	0.1	15
98	Anti-Tumour Necrosis Factor Therapy for Ulcerative Colitis. Drugs, 2006, 66, 2059-2065.	10.9	14
99	Systematic Analysis and Critical Appraisal of the Quality of the Scientific Evidence and Conflicts of Interest in Practice Guidelines (2005–2013) for Barrett's Esophagus. Digestive Diseases and Sciences, 2016, 61, 2812-2822.	2.3	13
100	Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. Inflammatory Bowel Diseases, 2019, 25, e143-e145.	1.9	13
101	The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy. Inflammatory Bowel Diseases, 2019, 25, 998-1005.	1.9	13
102	High Self-efficacy Predicts Adherence to Surveillance Colonoscopy in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 1602-1610.	1.9	12
103	Immune-mediated Reactions to Anti-tumor Necrosis Factors in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 1176-1186.	1.9	12
104	Factors Associated with the Success of In Vitro Fertilization in Women with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2016, 61, 2381-2388.	2.3	12
105	Doctor Message Can Alter Patients' Behavior and Attitudes Regarding Inflammatory Bowel Disease and Colon Cancer. Inflammatory Bowel Diseases, 2012, 18, 1531-1539.	1.9	11
106	The Use of Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2018, 14, 415-425.	0.1	11
107	Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survey, expert rand panel, and patient focus groups. Inflammatory Bowel Diseases, 2012, 18, 2294-2300.	1.9	10
108	Characteristics of Inflammatory Bowel Disease Serology in Patients With Indeterminate Colitis. Journal of Clinical Gastroenterology, 2014, 48, 351-355.	2.2	10

#	Article	IF	CITATIONS
109	Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease. Journal of Crohn's and Colitis, 2016, 10, 507-509.	1.3	10
110	Identifying IBD Providers' Knowledge Gaps Using a Prospective Web-based Survey. Inflammatory Bowel Diseases, 2020, 26, 1445-1450.	1.9	10
111	Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy. World Journal of Gastroenterology, 2017, 23, 6197.	3.3	10
112	Targeted Physician Education and Standardizing Documentation Improves Documented Reporting with Inflammatory Bowel Disease Quality Measures in a Large Academic and Private Practice. Digestive Diseases and Sciences, 2018, 63, 36-45.	2.3	9
113	Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative. Journal of Managed Care & amp; Specialty Pharmacy, 2021, 27, 1129-1135.	0.9	8
114	Therapeutic Drug Monitoring of Biologics in Crohn's Disease. Gastroenterology Clinics of North America, 2022, 51, 299-317.	2.2	8
115	Reducing the Torment of Diarrhea. Journal of Clinical Gastroenterology, 2007, 41, 797-798.	2.2	7
116	Bone of Contention: Helicobacter pylori and Osteoporosis—Is There an Association?. Digestive Diseases and Sciences, 2019, 64, 2736-2739.	2.3	7
117	The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. Journal of Crohn's and Colitis, 2019, 13, 1217-1226.	1.3	7
118	Evaluation of the small bowel in inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2013, 7, 239-251.	3.0	6
119	A rare case series of concomitant inflammatory bowel disease, sporadic adenomas, and serrated polyposis syndrome. Journal of Crohn's and Colitis, 2014, 8, 1735-1739.	1.3	6
120	New role for azathioprine in case of switching anti-TNFs in IBD. Gut, 2020, 69, 1165-1167.	12.1	6
121	Review of Societal Recommendations Regarding Management of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic. Inflammatory Bowel Diseases, 2021, 27, 940-946.	1.9	6
122	Thyroid cancer and Crohn's disease: Association or coincidence?. Inflammatory Bowel Diseases, 2006, 12, 79-80.	1.9	5
123	Is It Prime Time for Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease?. Gastroenterology, 2019, 157, 922-924.	1.3	5
124	Health Maintenance Consensus for Adults With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1552-1563.	1.9	5
125	Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1423-1431.	3.3	5
126	Varicella zoster meningoradiculitis in Crohn's disease treated with 6-mercaptopurine. Inflammatory Bowel Diseases, 2011, 17, E109-E110.	1.9	4

#	Article	IF	CITATIONS
127	Utility of Emergency Department Use of Abdominal Pelvic Computed Tomography in the Management of Crohn's Disease. Journal of Clinical Gastroenterology, 2016, 50, 859-864.	2.2	4
128	How to Develop the Medical Neighborhood. Journal of Medical Systems, 2016, 40, 196.	3.6	4
129	Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All. Clinical Gastroenterology and Hepatology, 2018, 16, 1829-1831.	4.4	4
130	Varicella zoster virus infection in patients with inflammatory bowel disease. Gastroenterology and Hepatology, 2013, 9, 56-8.	0.1	4
131	Overview of Therapeutic Drug Monitoring of Biologic Agents in Patients With Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2017, 13, 556-559.	0.1	4
132	Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. Journal of Clinical Medicine, 2021, 10, 5642.	2.4	4
133	Proactive Therapeutic Drug Monitoring of Adalimumab in Patients With Crohn's Disease. Gastroenterology, 2023, 164, 164-165.	1.3	4
134	Infliximab decreases colectomy rates in moderate to severe ulcerative colitis. Inflammatory Bowel Diseases, 2011, 17, 1626-1628.	1.9	3
135	Cryptosporidiosis masquerading as a Crohn's flare. Inflammatory Bowel Diseases, 2011, 17, E133-E134.	1.9	3
136	It Is Time to Treat to Trough: Staying Ahead of the Curve in Biologic Testing. Clinical Gastroenterology and Hepatology, 2015, 13, 2384.	4.4	3
137	Histological healing beyond endoscopic healing in ulcerative colitis: Shall we target the "ultra-deep― remission?. Digestive and Liver Disease, 2017, 49, 1332-1333.	0.9	3
138	Deâ€escalating medical therapy in Crohn's disease patients who are in deep remission: A RAND appropriateness panel. GastroHep, 2019, 1, 108-117.	0.6	3
139	Proactive Adalimumab Monitoring in Inflammatory Bowel Disease: Current Data and Future Perspectives. Journal of Crohn's and Colitis, 2020, 14, 878-879.	1.3	3
140	A Survey Study of Gastroenterologists' Views on Dysplasia Surveillance and Chromoendoscopy in IBD. Inflammatory Bowel Diseases, 2020, 26, e59-e61.	1.9	3
141	Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 854-855.	4.4	3
142	Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series. Digestive Diseases and Sciences, 2021, , 1.	2.3	3
143	Choosing the right biologic for complications of inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2022, 16, 235-249.	3.0	3
144	Response to Dr. Spada and Colleagues. American Journal of Gastroenterology, 2007, 102, 1543-1544.	0.4	2

#	Article	IF	CITATIONS
145	Infusion Reactions Related to Infliximab Therapy Are Not Usually Associated with Drug Discontinuation. Journal of Rheumatology, 2012, 39, 1500-1502.	2.0	2
146	P-084 Self-Reported Health Maintenance Behaviors in a Population of Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, S58-S59.	1.9	2
147	Inflammatory Bowel Disease-Related Abstracts Presented at National Conferences in the USA Are Frequently Unpublished as Full Manuscripts. Digestive Diseases and Sciences, 2017, 62, 352-357.	2.3	2
148	Câ€reactive protein as a predictor of low trough infliximab concentrations in patients who lose response to infliximab. Journal of Digestive Diseases, 2017, 18, 678-683.	1.5	2
149	Editorial: realâ€world shortâ€ŧerm effectiveness of ustekinumab in 305 patients with Crohn's disease—results from the ENEIDA registry. Alimentary Pharmacology and Therapeutics, 2019, 50, 599-600.	3.7	2
150	Tu1830 – Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients with Inflammatory Bowel Disease. Gastroenterology, 2019, 156, S-1141.	1.3	2
151	Evidence Supporting High-Dose Use of Biologics in Clinical Practice. Current Treatment Options in Gastroenterology, 2020, 18, 408-422.	0.8	2
152	Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay. Journal of Clinical Medicine, 2020, 9, 2840.	2.4	2
153	Editorial: is there a role for monitoring intermediate <scp>antiâ€TNF</scp> drug concentrations in <scp>IBD</scp> ?. Alimentary Pharmacology and Therapeutics, 2022, 55, 1049-1050.	3.7	2
154	Assessing the repercussions of COVID-19 pandemic on symptoms, disease management, and emotional well-being in patients with inflammatory bowel disease: a multi-site survey study. Scandinavian Journal of Gastroenterology, 2022, 57, 406-414.	1.5	2
155	PUCCINI: Safety of Anti-TNF in the Perioperative Setting. Gastroenterology, 2022, 163, 44-46.	1.3	2
156	Targeting TNF in postoperative recurrence of Crohn's disease. Inflammatory Bowel Diseases, 2009, 15, 1925-1926.	1.9	1
157	Vaccination in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2011, 106, 168.	0.4	1
158	Lectin-reactive Anti-α-Gal in Patients with Crohn's Disease. Inflammatory Bowel Diseases, 2013, 19, 2796-2800.	1.9	1
159	Editorial: therapeutic deâ€escalation of antiâ€tumour necrosis factor therapy – is less enough?. Alimentary Pharmacology and Therapeutics, 2017, 45, 1265-1266.	3.7	1
160	Response. Gastrointestinal Endoscopy, 2020, 91, 719-720.	1.0	1
161	Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 1085-1086.	3.7	1
162	Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases. JAMA - Journal of the American Medical Association, 2021, 326, 1067.	7.4	1

#	Article	IF	CITATIONS
163	You Say Goodbye and I Say Aloe. , 2004, 10, 693-695.		Ο
164	Comparative effectiveness research in inflammatory bowel disease: prospects and challenges. Expert Review of Gastroenterology and Hepatology, 2012, 6, 405-407.	3.0	0
165	Commentary: irritable bowel syndrome and the <scp>CDAI</scp> – misleading activity by straw men; authors' reply. Alimentary Pharmacology and Therapeutics, 2013, 37, 1021-1022.	3.7	Ο
166	Crohn Disease. JAMA - Journal of the American Medical Association, 2014, 312, 1708.	7.4	0
167	Colonoscopy Is Appropriately Utilized In Most Cases Following a Fair Bowel Prep. American Journal of Gastroenterology, 2014, 109, 1289.	0.4	0
168	In reply–Clinical Practice Guidelines: Still Miles to Go…. Mayo Clinic Proceedings, 2014, 89, 860-861.	3.0	0
169	Reply to Use of CT Scan in Ulcerative Colitis Patients Presenting to the Emergency Department. Inflammatory Bowel Diseases, 2015, 21, E21.	1.9	Ο
170	Reply. Clinical Gastroenterology and Hepatology, 2017, 15, 1638-1639.	4.4	0
171	Response to Reinink. American Journal of Gastroenterology, 2017, 112, 1893-1894.	0.4	Ο
172	Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 465-466.	1.9	0
173	Editorial: early postâ€induction antiâ€ <scp>TNF</scp> drug monitoring can predict longâ€term therapeutic outcomes in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 436-437.	3.7	0
174	Reply. Clinical Gastroenterology and Hepatology, 2018, 16, 598-599.	4.4	0
175	Integrin Calculus: The Predictive Power of Vedolizumab Concentrations in IBD Therapy. Digestive Diseases and Sciences, 2019, 64, 1397-1398.	2.3	Ο
176	The cost and benefit of anti-TNF therapy from a population perspective—for what it's worth. Annals of Translational Medicine, 2019, 7, S388-S388.	1.7	0
177	Cannabis and Inflammatory Bowel Disease: All Smoke and Mirrors?. Journal of Crohn's and Colitis, 2021, 15, 1785-1786.	1.3	Ο
178	Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe Group. Gastroenterology and Hepatology, 2008, 4, 713-20.	0.1	0
179	Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology. Digestive Diseases and Sciences, 2022, , 1.	2.3	0
180	Letter: is blindly stopping thiopurines without confirming adequate <scp>antiâ€TNF</scp> concentrations shortsighted?. Alimentary Pharmacology and Therapeutics, 2022, 55, 887-888.	3.7	0